Table 3.

Data from continuous glucose monitoring (CGM).

	Mean ± s.d. in Group A receiving prednisolon placebo/curcumin placeboa	Mean ± s.d. in Group B receiving prednisolone/curcumin placeboa	Mean ± s.d. in Group C receiving prednisolone/ curcumina	Difference between Group B and Group A, mean value (CI)b	P value (B vs A)	Difference between Group C and Group A mean value (CI)b	P value (C vs A)	Difference between Group C and Group B mean value (CI)b	P value (C vs B)
Percentage of time spent in euglycaemia (4−7.8 mmol/L) (%)	87.1 ± 13.0	82.5 ± 13.2	85.5 ± 6.9	4.6 (−19.3; 10.1)	0.511	−1.6 (−14.1; 10.8)	0.772	2.9 (−8.7; 13.6)	0.587
Percentage of time spent in hypoglycaemia (<4 mmol/L) (%)	12.6 ± 12.5	3.4 ± 6.9	8.0 ± 8.1	−6.2 (−18.2; 5.9)	0.276	−4.6 (−16.9; 7.7)	0.426	1.6 (−6.5; 9.7]	0.682
Percentage of time spent in hyperglycaemia (>7.8 mmol/L) (%)	0.3 ± 0.6	11.1 ± 9.1	6.6 ± 4.5	10.6 (3.1; 18.4)	0.012	6.2 (2.5; 10.0)	0.006	−4.5 (−12.5; 3.5)	0.237
Mean interstitial glucose (mmol/L)	4.8 ± 0.3	5.9 ± 0.5	5.6 ± 0.4	1.1 (0.6; 1.5)	0.0002	0.8 (0.44; 1.19)	0.0004	−0.3 (−0.7; 0.2)	0.242
CV of interstitial glucose	0.15 ± 0.04	0.24 ± 0.04	0.23 ± 0.02	0.08 (0.04; 0.13)	0.002	0.07 (0.03; 0.11)	0.002	−0.01 (−0.05; 0.03)	0.510
LBGI	3.7 ± 1.3	2.9 ± 1.1	2.8 ± 1.0	−0.9 (−2.3; 0.5)	0.207	−1.0 (−2.4; 0.4)	0.136	0.1 (−1.0; 1.3)	0.822
HBGI	0.3 ± 0.4	1.6 ± 0.9	1.3 ± 0.5	1.2 (0.4; 2.0)	0.006	1.0 (0.5; 1.4)	0.0005	−0.3 (−1.1; 0.5)	0.468

^aParameters calculated from data recorded from 8:00 h at the day of prednisolone/prednisolone placebo treatment initiation until second magnetic resonance spectroscopy or the night before experimental day #2 whichever came first. ^bWelch two-sample t test. CV, coefficient of variance; HBGI, high blood glucose index; LBGI, low blood glucose index.

CV, coefficient of variance; HBGI, high blood glucose index; LBGI, low blood glucose index.